Antiplatelet Therapy
To reduce risk of stent thrombosis, it was recommended that aspirin (81-200 mg daily) should be administered preprocedure and continued indefinitely, and ticlopidine (200 mg daily) should be administered concomitantly with aspirin and for a period of 3 months post-procedure in Japan. However, the management of antiplatelet therapy; initiation and discontinuation, including unavoidable ticlopidine discontinuation due to side effects or surgical operation, was left to the discretion of each cardiologist at participating study sites.
Data Collection and Management
The post-marketing surveillance databases were developed by Johnson & Johnson K.K. in Japan. Detailed demographics, clinical, angiographic and procedural information including complications were gathered for each patient. The data have been entered into case report forms by participating sites and collected by Johnson & Johnson K.K. Follow-up data were collected at 3, 8, 12 months and will be collected yearly up to 5 years. Angiographic data on 1,063 of 2,459 lesions were analyzed by an independent core laboratory (Cardiocore, Tokyo, Japan) and the remaining angiograms were analyzed by on-site quantitative coronary angiography (QCA). An independent safety and efficacy evaluation committee adjudicated all reported and suspected major adverse cardiovascular events (MACE) defined as death, myocardial infarction (MI) and target lesion revascularization (TLR) by PCI or by coronary artery bypass graft surgery (CABG); stent thromboses; and target vessel revascularization (TVR) by PCI or CABG. The adjudications were based on the information contained in the case report form and on the responses to queries addressed to the participating study sites.
Deaths were classified as cardiac or non-cardiac based on SIRIUS trial protocol definition, so unidentified death, that was any death in which a cardiac cause could not be excluded was classified as cardiac in this study. MI were classified as Q wave and non-Q wave by the physicians' discretions on the basis of ECG changes and/or a rise in creatine kinase enzyme concentration above twice the upper normal limit. If no information to judge classification of MI was available, it was classified as unidentified. TLR were based on the SIRIUS trial protocol definition and, all reported re-interventions inside the implanted stent or within 5 mm proximal or distal to the stent were classified as TLR. Repeated PCI in the same vessel was recorded as non-target lesion TVR (non-TL TVR). Stent thrombosis was classified based on Academic Research Consortium (ARC) definition as 'definite' or 'probable', and 'early' (0-30 days after implantation) or 'late' (31-360 days after implantation).
Statistical Analysis
Data were expressed as mean ± SD for continuous variables and as frequencies for the categorical variables. Categorical variables that were significant on univariate analysis to determine their independent relation to TLR, were analyzed by the Fisher's exact test. Statistical significance was declared if the 2-sided probability value was <0.05. Eventfree (death free, death + MI free, MACE free) and administration of ticlopidine during the 12 months follow-up period 
Results

Patients and Follow-up Compliance
A total of 2,054 cases/2,464 lesions were enrolled. The mean age was 67.1±10.1, 75.6% were men, and 43.3% were diabetics including 10.1% with insulin treatment. Glycoprotein IIbIIIa inhibitors were not used because they were unavailable in Japan. The baseline characteristics are detailed in Table 1 . Note that this study included 1,401 cases (68.3%) that could be considered high risk, so called 'offlabel use'. This included acute MI treatment, unprotected left main coronary artery, bifurcation, ostial, restenotic lesion, non-native vessel, chronic total occlusion or long lesions over 30 mm.
Lesion Characteristics
A total of 3,279 SES were implanted into 2,458 lesions during the index procedure. Delivery failure of SES was observed in 5 lesions, and thus the initial success rate of implantation of SES was 99.8% (2,453/2,458 lesions). The stent lengths were 13 to 33 mm and diameters between 2.5 and 3.5 mm. Lesion characteristics are shown in Table 2 . It is noteworthy that the average of maximum deployment pressure of SES was high, post-dilatation was performed with another balloon in 46.4%, intravascular ultrasound (IVUS) was used in 77.2% of the procedure.
Clinical Follow-up
Follow-up data were available for 2,037 patients at 3 months, and 1,986 patients at 1 year, representing 99.3% and 96.8% compliance, respectively. Follow-up data are listed in Table 3 . Event free survival curves are shown in Figure. 
Angiographic Follow-up
Angiographic follow-up data at 8 months were available in 1,752 patients (85.4%), which included 812 patients enrolled for core laboratory analysis ( Table 4) . The insegment binary restenosis rate was 9.0% (187/2,087 lesions) in overall QCA data. The core-lab QCA data showed the instent binary restenosis rate and late loss were 8.0% (76/952 lesions) and 0.20±0.50 mm.
Predictors of TLR
Predictors of TLR are shown in Table 5 . Significant predictors of TLR were multiple vessel disease, diabetes, dialysis, restenotic lesions, small reference vessel, long lesion and calcified lesions. The result of univariate analysis indicated dialysis was the most significant predictor of TLR in this study.
Antiplatelet Drugs and Stent Thrombosis
Aspirin was administrated continuously to 1 year after stent implantation. Meanwhile the use of ticlopidine decreases significantly approximately 3 months partly as shown in Figure B because the recommendation of administration period for ticlopidine was at least 3 months after implantation in the SES instruction for use in Japan. The reasons for discontinuation of ticlopidine were as follows: 42.3% secondary to ticlopidine side effects, 38.9% judg- ment of full-term, 4.7% from complications other than ticlopidine side effects, 3.4% non-compliance or errors in description, 2.7% due to surgical operations, and 8.1% for unknown reasons. Detailed data of ticlopidine side effects were as follows: 24.2% hepatic disorder, 10.1% skin rash, 7.3% any abnormal biochemical test, 0.3% deterioration of renal function and 0.3% agranulocytosis. No thrombotic thrombocytopenic purpura was reported in this study. In this situation, the rates of 'definite' and 'definite or probable' thrombosis within 1 year were 0.30% and 0.40%, respectively ( Table 6 ). In the total of 8 patients, 2 patients took dual antiplatelet drugs, 1 took only aspirin, and the remaining patients discontinued dual APT (unknown, 3, 6, 55 and 149 days before thrombosis occurred, respectively).
Discussion
The J-PMS is a unique study because the initial dual antiplatelet regimen was aspirin plus low dose ticlopidine for all patients without exception. Clopidogrel had not been approved for use in Japan during the conduct of this study. There were no data to confirm the efficacy of ticlopidine as an antiplatelet drug for DES implantation. Additionally, there was a concern about the risk of severe ticlopidine side effects. Thus, the J-PMS was mandated by the government.
Pharmacologic studies show there is a linear increase in antiplatelet effects an increasing dose of ticlopidine. The 90% of maximal effect is seen approximately 200 to 250 mg and it is almost a plateau with only a small increase up to 500 mg. [16] [17] [18] Thus, the usual dose selection was 500 mg, which was almost doubling the dose for reaching plateau. In China, 250 mg/day ticlopidine therapy was suggested to prevent side effects. 19 In Japan, ticlopidine was approved at the dose of 300 mg/day in the 1980 s but the Japanese physicians reduced the dose to 200 mg/day due to frequent side effects of hepatic disorder. This dose has been used in daily practice for more than 1 decade.
Only limited amounts of data were available comparing ticlopidine 200 mg and clopidogrel 75 mg. There is a doubleblind randomized study comparing ticlopidine 200 mg and clopidogrel 75 mg. 20 The study did no show any significant difference in the prevention of strokes between the 2 groups; however, the frequency of side effects almost doubled in the ticlopidine group as in the clopidogrel group. The REACH registry in Japan arm showed the event rate using ticlopidine 200 mg/day was similar to other countries. 21 These observations suggest that the antiplatelet effect of ticlopidine 200 mg/day was sufficient to prevent thrombotic events in Japan with lower side effect rate of ticlopidine. 22, 23 A benefit of this study is the limited case selection bias because no other DESs were available during the study period in Japan. On the contrary, there were several Japanspecific risk factors such as small reference vessel diameter (the average was 2.47 mm), high percent of diabetics (43.3%) and off-label use (68.3%), including 11.2% total occlusion. Despite treating high risk lesions with low dose ticlopidine, J-PMS data showed event rates are equal to or lower than other studies in other countries. [2] [3] [4] [5] 7, 8, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] The rates at 1 year of definite and probable stent thrombosis, MACE and target vessel failure: 0.40%, 7.3% and 9.3% are acceptable because other registry studies showed these results ranged from 0.4% 3 to 1.3%; 22 5.8% 7 to 15%; 23 and 9.8% 3 to 12%, 21 respectively. [2] [3] [4] [5] 7, 8, [24] [25] [26] [27] [28] [29] [30] [31] [32] Before the launch of the CYPHER stent in Japan, educational instruction courses were conducted all over the country to teach high maximal inflation pressure [34] [35] [36] [37] and confirmation of stent full expansion with IVUS, if possible. [38] [39] [40] [41] J-PMS showed high rate of IVUS usage (77.2%) and high inflation pressure (16.0± 3.5 atm). These courses could have helped to achieve the current favorable results, even with the high percentage of off-label use. 42 Predictors of hard endpoints (death plus MI) and TLR were shown in Table 5 . We found that dialysis was the strongest predictor of not only TLR but also death plus MI. This study included 5.1% dialysis patients which was a higher rate compared to other studies. Results of DESs for dialysis patients have not been clarified but data from this study might suggest we need to focus on the data of dialysis patients. 43 Limitations of this study are as follows: these were interim results of J-PMS study with 1 year follow-up rate 96.8%. The study is mandated up to 5-year follow-up, so the data will be updated and finalized by completing follow-up with all patients. Platelet reaction to drugs might be different in other races and the data should be confirmed in other countries. QCA was performed in only half of the patients at the independent core laboratory. In conclusion, this study showed acceptable results with SES with aspirin plus low dose of ticlopidine (200 mg/day) compared to other registry studies with aspirin plus clopidogrel [2] [3] [4] [5] 7, 8, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] although approximately half of the patients quitted ticlopidine within 1 year mainly due to side effects. Low dose of ticlopidine administration might be a cost-effective substitute of clopidogrel after SES implantation in Japanese populations. Values are n (%). *Exclude one case with procedure failure (MI occurred during PCI procedure). Abbreviations see in Tables 1,3. 
